SI-BONE Inc

SI-BONE Inc(SIBN)股票分析

$21.230

-1.119 (-5.27%)收盘时

Loading chart…
最高
22.250
开盘
22.250
成交量加权均价
21.48
成交量
1.25M
市值
512.18M
最低
20.950
成交额
26.83M
企业价值/息税折旧摊销前利润(TTM)
-67.17

SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants, and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.

AI 分析 of SI-BONE Inc (SIBN)

买入

SI-BONE Inc is a good buy right now due to its current price of $21.48, a strong RSI of 78.24 indicating momentum, and a gross margin of 79.54% which showcases effective cost management. The company has also received FDA clearance for its Onyx system, which is expected to drive future revenue growth. However, the main risk is the negative earnings per share (EPS) of -0.09 projected for the next quarter, indicating ongoing losses.

分析师评级(4)

上行空间 +18.56%
买入
4 买入
0 持有
0 卖出
当前: 21.23
最低
23.00
平均
25.17
最高
28.00

UBS

2026-08-04

目标价

$25

买入

TD Cowen

2026-08-04

目标价

$20

买入

Truist

2026-08-04

目标价

$23

买入

UBS

2026-07-28

目标价

$24

买入

Truist

2026-07-16

目标价

$21

买入

估值指标

SI-BONE Inc(SIBN)当前预期市盈率为 0.00,5 年平均预期市盈率为 -18.25。

预期市盈率

严重高估
5 年均值 P/E
-18.25
当前P/E
0.00
高估
-11.11
低估
-25.39

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
45.87
当前EV/EBITDA
-67.17
高估
388.80
低估
-297.07

预期市销率

合理
5 年均值 P/S
4.24
当前P/S
3.74
高估
5.68
低估
2.81

Alphio AI 对 SIBN 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%SIBN

$24.86

情景价格

基

基准

基准 · 50%SIBN

$23.43

情景价格

悲

悲观

悲观 · 25%SIBN

$20.99

情景价格

持有 SIBN 的大户

P

Paradigm Capital Management, Inc.

+ 持有SIBN

-19.55%

3个月收益率

事件时间线

2026-09-28 (ET)

16:30:00

SI-Bone Receives FDA 510(k) Clearance for iFuse Granite Onyx System

2026-08-03 (ET)

17:00:00

Q2 Revenue of $56.0M Exceeds Consensus

17:00:00

Company Maintains FY26 Gross Margin Guidance at ~79%

2026-05-12 (ET)

16:20:00

Major Averages Finish Mixed as Semiconductor Stocks Pull Back

12:00:00

Nasdaq Declines as Semiconductor Stocks Pull Back

资讯

SIBN 常见问题 —— 由 Alphio AI 解答

SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants, and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

SI-BONE Inc is a good buy right now due to its current price of $21.48, a strong RSI of 78.24 indicating momentum, and a gross margin of 79.54% which showcases effective cost management. The company has also received FDA clearance for its Onyx system, which is expected to drive future revenue growth. However, the main risk is the negative earnings per share (EPS) of -0.09 projected for the next quarter, indicating ongoing losses.

4 analysts cover SIBN: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 25.17.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易